CELL PRESERVATION SERVICES INC — Department of Health and Human Services SBIR Phase I: 102

Description

The need for the development of new strategies for treatment of bladder cancer BC has experienced a palpable increase in the last few years While several options are currently under investigation many if not all remain suboptimal This is critical as it is estimated that in there were new cases and over deaths from BC worldwide In the US alone there were new cases and over deaths from BC This makes BC the th most prevalent and th deadliest cancer worldwide While various treatment options currently exist a number of issues have been reported including the high cost of treatment patient discomfort complications incomplete treatment procedural invasiveness and poor efficacy among others With a yr survival rate for BC patients ranging from to yielding a reported deaths in alone far above prostate or breast cancer there is an ever growing urgency and compelling need for the development of new strategies and devices to treat BC The intent of this project is to develop a new cystoscopic based thermo molecular treatment strategy and catheter system FrostBite BC for the treatment of BC employing a minimally invasive trans urethral outpatient procedure The prototype unit and preliminary data collected to date strongly support the potential of this approach The major goals of this Phase proposal are the following Develop the FrostBite BC catheter system and bench test it using non tissue engineering models Test this new treatment protocol in a homogeneous and heterogeneous cell population BC tissue engineered model TEM Test the ability of an adjunctive nutraceutical compound Vitamin D to sensitize BC cells to freeze injury cryosensitization thereby making cryoablation more effective while protecting normal cells and conduct a pilot in vivo study to validate development Phase will include optimizing the catheter device and procedure conducting pre clinical in vivo studies and determining the potential role of FrostBite BC launching a whole body immune response against metastatic disease in vivo The successful completion of this project will lead to a new minimally invasive cystoscopic compatible trans uretheral approach for the treatment of bladder and other urogenital cancers Once completed this project will provide for an effective minimally invasive treatment for patients afflicted with BC as well as other urologic based cancers resulting in improved patient survival quality of life and mitigating risk factors for cancer diagnosis This application proposes to develop a novel thermo molecular therapeutic strategy for the treatment of bladder cancer